Global Antibody Drugs (Central Nervous System Ailment, Allergic diseases, Cancer, Infections) Market 2014-2016 - & Forecasts to 2021 - Research and Markets

Research and Markets has announced the addition of the "Antibody Drugs Market: By Disease Cure (Central nervous system ailment, Allergic diseases, Cancer, Infections), By Strategic Analysis & Geography - Forecast (2014-2021)" report to their offering.

This report identifies the anti-body drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anti-body drugs market.

On the basis of diseases cured by anti-body drug type this report classified as follows covering all major types of diseases cured by these drugs: Central nervous system ailment, Allergic diseases, Cancer, Infections and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anti-body drugs in each of the region.

This report identifies all the major companies operating in the global anti-body drugs market. Some of the major companies' profiles in detail are as follows:

• Abbott Laboratories
• Bayer HealthCare AG
• Eli Lilly and Co.
• UCB Company
• Merck & Co.
• Johnson & Johnson

Key Topics Covered:

1. Antibody Drugs - Market Overview

2. Executive Summary

3. Antibody Drugs Market Landscape

4. Antibody Drugs - Market Forces

5. Antibody Drugs - Strategic Analysis

6. Global Antibody Drugs Market, By Disease Cure (2014-2021)

7. Global Antibody Drugs Market, By Geography (2014-2021)

8. Antibody Drugs - Market Entropy

9. Company Profiles (Top 10 Companies)

For more information about this report visit http://www.researchandmarkets.com/research/qp83q7/antibody_drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005905/en/